We analysed the risk of death and median overall survival for metastatic melanoma patients treated with anti-PD-1 classifying the patients according to demographics, distant metastasis stage and serum S100B and LDH levels at the beginning of therapy, and clinicopathological features of primary melanoma. This evidence concerns the gene S100B and metastatic melanoma.